Covid-19 Vaccine Update: Moderna vaccine effective against UK, SA strains and promising Israeli data

Joel Frank Independent Analyst

Moderna held a conference call to discuss earlier released results on how its vaccine performed against newer variants of Covid-19. Earlier in the day, the Co. had claimed that its vaccine is still effective against the UK and South African variants of the virus.

CEO Stephane Bancel, “we are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 Vaccine should be protective against these newly detected variants”.

“Out of an abundance of caution and leveraging the flexibility of our mRNA platform,” he continued, “we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic.”

Moderna's CMO Dr Zaks said that the company is looking at studying a third "booster" shot that would come 6-12 months after the second dose of their original Covid-19 vaccine and no sooner. Zaks said he expects the durability of the protection provided by the first two doses to last at least a year.

The study

Moderna took blood samples from eight people who had received two doses of the vaccine, and from primates that had also been immunized.

There was no impact on the level of neutralizing antibodies for the B.1.1.7 (UK) variant, meaning the company’s vaccine was equally as effective against the UK variant as the original. But for the South African variant, B.1.351, there was a sixfold reduction in the neutralizing antibody level, though Moderna said this was still above the quantity needed to offer protection shown in earlier tests on primates that were infected on purpose.

Promising data out of Israel

Israel’s Maccabi Health Services showed that out of the 128,600 Israeli participants in a study who had all received their second jab of the Pfizer/BioNTech vaccine, only 20 had tested positive for Covid-19 and none had been hospitalised or even experienced temperatures of above 38.5 degrees Celsius. The news serves as early evidence that mass vaccinations ought to be able to drastically reduce the spread and prevalence of Covid-19, as market participants have been holding out for.

AstraZeneca denies refutes reports of low efficacy

AstraZeneca has come out strongly refuted an earlier report in Handelsblatt claiming that their vaccine only had efficacy of 8% in over 65s.

The journalist who wrote the article tweeted that "we have confirmed the 8% with multiple sources familiar with the German vaccination policy. Our sources, including members of the government coalition, spoke on the condition of anonymity".

A spokesperson for AstraZeneca made a statement on Monday claiming that the report was "completely incorrect" and referenced the data published by the company back in November which demonstrated that "older adults showed strong immune responses to the vaccine, with 100% of older adults generating spike-specific antibodies after the second dose".

Author

Joel Frank

Independent Analyst

Joel Frank is an economics graduate from the University of Birmingham and has worked as a full-time financial market analyst since 2018, specialising in the coverage of how developments in the global economy impact financial asset

GBP/USD clings to gains near 1.3400

GBP/USD retreats after reaching a three-week high above 1.3430, challenging the 1.3400 yardstick on Thursday. Although easing political uncertainty in the UK helps the quid limit its downside, escalating tensions in the Middle East support the Greenback, keeping Cable under scrutiny.

EUR/USD: Daily gains appear capped by 1.1450

EUR/USD keeps the recovery in place and looks to consolidate its gains north of 1.1400 the figure at the end of the NA session on Thursday. The pair’s move higher appears in tandem with a modest pullback in the US Dollar despite geopolitical concerns in the Middle East remain unabated.

Gold flirts with two-day highs, approaches $4,130

Gold stages a modest rebound on Thursday, setting aside a three-day losing streak and managing to surpass the $4,100 mark per troy ounce. However, steady geopolitical tensions have revived concerns over persistently high global inflation, reinforcing expectations of higher rates across the board and somewhat curtailing the yellow metal’s upside potential.

AAVE eyes $100 after Stable Vaults launch

Aave edges higher above $90.00 at the time of writing on Thursday, amid broader price stabilization in the crypto market. The company has announced Stable Vaults, a platform that allows businesses to integrate fixed-rate stablecoin yield, mildly lifting sentiment in the ecosystem.

Japan may be changing its Yen strategy, but markets don’t look scared

Japan may be changing its intervention playbook, but that might not be enough to rescue the battered Yen. With USD/JPY hovering at four-decade highs, the currency’s weakness is being driven less by speculative pressure and more by a powerful structural force: the wide US-Japan rate gap.

Bye, forward guidance: How to trade when central banks choose silence

Central banks have spent years telling markets what might come next. Now, traders face the possibility that they say a lot less. From the Federal Reserve to the European Central Bank and the Bank of England, policymakers are pushing back against forward guidance.